Since 2006, the United States Food and Drug Administration has received 65 case reports of Nephrogenic Systemic Fibrosis in patients who were administered a gadolinium-based contrast agent.

According to officials with the FDA, the agency knew of only 25 cases of Nephrogenic Systemic Fibrosis linked to gadolinium-based MRI contrast agents prior to 2006. Since that time an additional 65 cases have been reported to the agency. The government body also indicates on its website that researchers have found gadolinium deposits in the skin of patients who developed NSF/NFD – information which the agency was unaware of prior to 2006.

Since first addressing concerns about gadolinium-based contrast agents and Nephrogenic Systemic Fibrosis on December 22, 2006, the agency has also learned of Nephrogenic Systemic Fibrosis cases in patients who received the recommend doses of the gadolinium-based contrast agents. The cases known to the FDA prior to that date stemmed from patients who received doses of gadolinium-based contrast agents above what is recommended.

If you have developed Nephrogenic Systemic Fibrosis after being administered a gadolinium-based contrast agent, please contact the Gadolinium Lawyers of Williams Kherkher by calling 800-761-3187.